-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15

Benzinga·06/30/2026 11:50:44
Listen to the news
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $12 to $15.